References

Abdulrahman GO Jr. The effect of multidisciplinary team care on cancer management. Pan Afr Med J. 2011;9:20.

Ahmed S, Berzon RA, Revicki DA, Lenderking WR, Moinpour CM, Basch E, et al. The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med Care. 2012;50(12):1060–70.

Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002;4:197–201.

Au A, Lam W, Tsang J, Yau TK, Soong I, Yeo W, et al. Supportive care needs in Hong Kong Chinese women confronting advanced breast cancer. Psychooncology. 2013;22(5):1144–51.

Brisken C. Hormonal control of alveolar development and its implications for breast carcinogenesis. J Mammary Gland Biol Neoplasia. 2002;7:39–48.

Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii11–9.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329–34.

Chang JH, Vines E, Bertsch H, Fraker DL, Czerniecki BJ, Rosato EF, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: The University of Pennsylvania experience. Cancer. 2001;91(7):1231–7.

Cleeland CS, Mayer M, Dreyer NA, Yim YM, Yu E, Su Z, et al. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. Breast. 2014;23(6):763–9.

Danesh M, Belkora J, Volz S, Rugo HS. Informational needs of patients with metastatic breast cancer: what questions do they ask, and are physicians answering them? J Cancer Educ. 2014;29(1):175–80.

de Melo Gagliato D, Jardim DL, Marchesi MS, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016;7(39):64431–46.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429–34.

Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103(22):1656–64.

Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284–98.

Elster N, Collins DM, Toomey S, Crown J, Eustace AJ, Hennessy BT. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. Breast Cancer Res Treat. 2015;149(1):5–15.

Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol. 2006;7(11):935–43.

Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;8:17.

Gao R, Davis A, McDonald TO, Sei E, Shi X, Wanf Y, et al. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet 2016;48:1119–30.

Gaston CM, Mitchell G. Information giving and decision-making in patients with advanced cancer: a systematic review. Soc Sci Med. 2005;61(10):2252–64.

Gil-Gil MJ, Martinez-Garcia M, Sierra A, Conesa G, Del Barco S, González-Jimenez S, et al. Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol. 2014;16(5):436–46.

Global Status of Advanced/Metastatic Breast Cancer: 2005–2015 Decade Report. Sponsored by Pfizer Oncology. March 2016. Available at http://www.abcglobalalliance.org/pdf/Decade-Report_Full-Report_Final.pdf. Accessed June 2018.

Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at http://globocan.iarc.fr/Default.aspx. Accessed June 2018.

Grimm SL, Hartig SM, Edwards DP. Progesterone receptor signaling mechanisms. J Mol Biol. 2016;428:3831–49.

Hardie H, Leary A. Value to patients of a breast cancer clinical nurse specialist. Nurs Stand. 2010;24(34):42–7.

Harding V, Afshar M, Krell J, Ramaswami R, Twelves CJ, Stebbing J. 'Being there' for women with metastatic breast cancer: a pan-European patient survey. Br J Cancer. 2013;109(6):1543–8.

Hattori M, Iwata H. Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable? Chin Clin Oncol. 2018. [Epub ahead of print].

Here & Now Report, Novartis Oncology. 2013. Available at http://wearehereandnow.com/files/here-and-now-report.pdf. Accessed June 2018.

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5).

Hurvitz SA, Lalla D, Crosby RD, Mathias SD. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. Breast Cancer Res Treat. 2013;142(3):603–9.

Joosten EA, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CP, de Jong CA. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom. 2008;77(4):219–26.

Kashaf MS, McGill E. Does shared decision making in cancer treatment improve quality of life? A systematic literature review. Med Decis Making. 2015;35(8):1037–48.

Kehl KL, Landrum MB, Arora NK, Ganz PA, van Ryn M, Mack JW, et al. Association of actual and preferred decision roles with patient-reported quality of care: shared decision making in cancer care. JAMA Oncol. 2015;1(1):50–8.

Kent EE, Malinoff R, Rozjabek HM, Ambs A, Clauser SB, Topor MA, et al. Revisiting the surveillance epidemiology and end results cancer registry and medicare health outcomes survey (SEER-MHOS) linked data resource for patient-reported outcomes research in older adults with cancer. J Am Geriatr Soc. 2016;64(1):186–92.

Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012;344:e2718.

Kissane DW, Grabsch B, Love A, Clarke DM, Bloch S, Smith GC. Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. Aust N Z J Psychiatry. 2004;38:320–6.

Koopman T, Buikema HJ, Hollema H, de Bock GH, van der Vegt B. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement. Breast Cancer Res Treat. 2018;169(1):33–42.

Lee A, Djamgoz MBA. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110–22.

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of 24 triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One 2016;11:e0157368.

Luoma ML, Hakamies-Blomqvist L. The meaning of quality of life in patients being treated for advanced breast cancer: a qualitative study. Psycho-Oncology. 2004;13(10):729–39.

Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8:23–31.

Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(6):809–15.

Mayer M, Hunis A, Oratz R, Glennon C, Spicer P, Caplan E, et al. Living with metastatic breast cancer: a global patient survey. Community Oncol. 2010;7(9):406–12.

McKee MJ, Keith K, Deal AM, Garrett AL, Wheless AA, Green RL, et al. A multidisciplinary breast cancer brain metastases clinic: The University of North Carolina experience. Oncologist. 2016;21(1):16–20.

Milbury K, Badr H. Sexual problems, communication patterns, and depressive symptoms in couples coping with metastatic breast cancer. Psycho-Oncology. 2013;22:814–22.

Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the national cancer institute’s surveillance, epidemiology, and end results database. Cancer 2007;110:876–84.                                                                                                   

Mosher CE, Duhamel KN. An examination of distress, sleep, and fatigue in metastatic breast cancer patients. Psychooncology. 2012;21(1):100–7.

Mystakidou K, Parpa E, Tsilika E, Pathiaki M, Gennatas K, Smyrniotis V, et al. The relationship of subjective sleep quality, pain, and quality of life in advanced cancer patients. Sleep. 2007;30(6):737–42.

Palliative care in cancer. National Cancer Institute. 2017. Available at www.cancer.gov/about-cancer/advanced-cancer/care-choices/palliative-care-fact-sheet. Accessed June 2018.

O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20–9.

Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, et al. Triple-negative breast cancer: current state of the art. Tumori. 2010;96:875–88.

Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst. 2014;106(7).

Rosen JM. Hormone receptor patterning plays a critical role in normal lobuloalveolar development and breast cancer progression. Breast Dis. 2003;18:3–9.

Saha Roy S, Vadlamudi RK. Role of estrogen receptor signalling in breast cancer metastasis. Int J Breast Cancer. 2012;2012:654698.

Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, et al. Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Ann Oncol. 2012;23(4):853–9.

Sainsbury R, Haward B, Rider L, Johnston C, Round C. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet. 1995;345(8960):1265–70.

Sant M, Allemani C, Capocaccia R, Hakulinen T, Aareleid T, Coebergh JW, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003;106(3):416–22.

Santa-Maria CA, Park SJ, Jain S, Gradishar WJ. Breast cancer and immunology: biomarker and therapeutic developments. Expert Rev Anticancer Ther. 2015;15(10):1215–22.

Shah R, Rosso K, Nathanso SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014;5:283–98.

Spronk I, Burgers JS, Schellevis FG, van Vliet LM, Korevaar JC. The availability and effectiveness of tools supporting shared decision making in metastatic breast cancer care: a review. BMC Palliat Care. 2018;17(1):74.

Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;Issue 4. Art. No.: CD001431.

Stewart BW, Wild CP. International Agency for Cancer Research, World Health Organization. World cancer report 2014.

Tometich DB, Mosher CE, Hirsh AT, Rand KL, Johns SA, Matthias MS, et al. Metastatic breast cancer patients' expectations and priorities for symptom improvement. Support Care Cancer. 2018. [Epub ahead of print].

Tungsukruthai S, Petpiroon N, Chanvorachote P. Molecular mechanisms of breast cancer metastasis and potential anti-metastatic compounds. Anticancer Res. 2018;38(5):2607–18.

Vinod SK, Sidhom MA, Delaney GP. Do multidisciplinary meetings follow guideline-based care? J Oncol Pract. 2010;6(6):276–81.

Vondeling GT, Menezes GL, Dvortsin EP, Jansman FGA, Konings IR, Postma MJ, et al. Burden of early, advanced and metastatic breast cancer in The Netherlands. BMC Cancer. 2018;18(1):262.

Wanchoo P, Larrison C, Rosenberg C, Ko N, Cantril C, Moeller N, et al. Identifying educational needs of the multidisciplinary cancer team in the treatment of metastatic breast cancer. J Natl Compr Canc Netw. 2017;15(2):205–12.

Warren M, Mackie D, Leary A. The complexity of non face-to-face work with patients affected by metastatic breast cancer and their carers. The 'hidden consultations' of the clinical nurse specialist. Eur J Oncol Nurs. 2012;16(5):460–4.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.

Yi TI, Kim BK, Ha SA, Lim JY. The relationships between determination of treatment success and emotional factors in patients with chronic musculoskeletal pain. Ann Rehabil Med. 2014;38(1):77–83.

Login/ Register Maximise Minimise